Top Suppliers:I want be here
Related CAS#:
2088525-48-6 2295965-53-4
1935233-52-5 2133820-14-9
2172852-96-7 1646288-39-2
90647-02-2 2091248-53-0
1980023-80-0 2012535-75-8

71486-22-1

71486-22-1 structure
71486-22-1 structure
  • Name: Vinorelbine
  • Chemical Name: vinorelbine
  • CAS Number: 71486-22-1
  • Molecular Formula: C45H54N4O8
  • Molecular Weight: 778.932
  • Catalog: API Antineoplastic agents Natural source antineoplastic agents
  • Create Date: 2018-05-10 08:00:00
  • Modify Date: 2026-07-01 16:44:36
  • Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.
Name vinorelbine
Synonyms NSC32797
Aspidospermidine-3-cboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl- , methyl ester, (2b,3b,4b,5a,12R,19a)
vinorebline
3',4'-didehydro-4'-desoxy-8'-norvincaleucoblastine
5-Nonylthio-8-methylthio-chinolin
vinorelbine dittrate ,navelbine,nvb
vinorelbene
Aspidospermidine-3-cboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2β,3β,4β,5α,12R,19α)
methyl (3,3a1r,4r,5s,5,10br)-4-acetoxy-3a-ethyl-9-((6r,8s)-4-ethyl-8-(methoxycbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1h-indolizino[8,1-cd]cbazole-5-cboxylate
Methyl (3,3a1R,4R,5S,5,10bR)-4-acetoxy-3a-ethyl-9-((2R,6R,8S)-4-ethyl-8-(methoxycbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]cbazole-5-cboxylate
C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy
Vinorelbine Impurity C (2R,8S-Isomer)
KW 2307 base
5-Noranhydrovinblastine
Vinorelbine, 10 mM in DMSO
Vinblastine Impurity K
Navelbine base
Vinorelbine from Cathanthus roseus (L.) G. Don
Methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12S)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
3’,4’-didehydro-4’-deoxy-c’-norvincaleukoblastin
Vinorelbine (KW-2307)
8-methylsulfanyl-5-nonylsulfanyl-quinoline
VINORELBINE
(2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(Methoxycbonyl)-2,6-Methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-Methoxy-1-Methyl-aspidosperMidine-3-ca
NVBKW-2307
NSC-32797
vinorelbine D-ttrate
5'-noranhydrovinblastine
AspidosperMidine-3-cboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8
Methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12S)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methox y-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
Vinorelbine //BP
3’，4'-Didehydro-4ideoxy-C’-norvincaleukoblastine
Aspidospermidine-3-cboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12R,19a)- (9CI)
ANX-530, KW-2307, 5'-Noranhydrovinblastine
3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine
Vinorelbine(Navelbine)
CL069
Navelbine(R)
Aspidospermidine-3-cboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12b,19a)
Quinoline,8-(methylthio)-5-(nonylthio)
nor-5’-anhydrovinblastine
Description Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.
Related Catalog
In Vitro Vinorelbine (0.5-5 nM) inhibits cell proliferation by 50% (IC50) at concentrations of 1.25 nM. At concentration of 8 nM vinorelbine, no cells are in anaphase[1]. Vinorelbine time-dependently induces the p53 and p21WAFI/CIP1 expression in androgen-dependent (AD) and- independent (AI) prostate cancer cell lines. Vinorelbine stimulates reporter genes in a concentration-dependent manner[2].
In Vivo After vinorelbine treatment, the first neutropenicepisode occurred after the first (4 dogs), second (1), or sixth(1) vinorelbine treatment in the dogs[3]. Vinorelbine is tolerated at a weekly interval in tumor-bearing cats, with an MTD of 11.5 mg/m2[4].
Animal Admin As defined by the study, VRL1 is diluted in 0.9% NaCl to a concentration of 1.5 mg/mL, and given IV over 5 minutes. The intended treatment interval is 7 days for up to 4 treatments. After receiving 4 weekly doses, cats are eligible to continue VRL treatment every 2 weeks at the owner's expense.
References

[1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32.

[2]. Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73.

[3]. Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9.

[4]. Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8.
Density 1.4±0.1 g/cm3
Molecular Formula C45H54N4O8
Molecular Weight 778.932
Exact Mass 778.394165
PSA 133.87000
LogP 4.69
Index of Refraction 1.676
Storage condition 2-8C

CHEMICAL IDENTIFICATION

RTECS NUMBER :
RD2530000
CHEMICAL NAME :
C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-
CAS REGISTRY NUMBER :
71486-22-1
LAST UPDATED :
199706
DATA ITEMS CITED :
1
MOLECULAR FORMULA :
C45-H54-N4-O8
MOLECULAR WEIGHT :
779.03

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
26 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
GTKRDX Gan to Kagaku Ryoho. Cancer and Chemotherapy. (1-8-9 Yaesu, Chuo-ku, Tokyo 103, Japan) V.1- 1974- Volume(issue)/page/year: 10,1050,1983
89384-09-8 structure

89384-09-8

~79%

71486-22-1 structure

71486-22-1

Literature: Gueritte; Pouilhes; Mangeney; et al. European Journal of Medicinal Chemistry, 1983 , vol. 18, # 5 p. 419 - 424
89368-94-5 structure

89368-94-5

~77%

71486-22-1 structure

71486-22-1

Literature: Gueritte; Pouilhes; Mangeney; et al. European Journal of Medicinal Chemistry, 1983 , vol. 18, # 5 p. 419 - 424
89368-94-5 structure

89368-94-5

~76%

89384-09-8 structure

89384-09-8

71486-22-1 structure

71486-22-1

Literature: European Journal of Medicinal Chemistry, , vol. 18, # 5 p. 419 - 424
38390-45-3 structure

38390-45-3

~%

71486-22-1 structure

71486-22-1

Literature: European Journal of Medicinal Chemistry, , vol. 18, # 5 p. 419 - 424
Precursor  1

DownStream  1

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:71486-22-1 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 71486-22-1 | Chemsrc address: https://m.chemsrc.com/en/baike/600630.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2026 ChemSrc All Rights Reserved